1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends
  4. > Biosimilars: US Payer Perspectives

Biosimilars: US Payer Perspectives

  • April 2015
  • -
  • Firstword Pharma

Summary

Table of Contents




Biosimilars: US Payer Perspectives pulls back the curtain on the US biologics market and provides detailed and actionable insights from 12 expert US payers from a range of different organisations, including Pharmacy Benefit Managers, Managed Care Organisations and Integrated Delivery Networks. In addition, receive an Advisory Highlights management summary which covers key findings from the report.

Spending on biologics is set to reach $100 billion in the US over the next couple of years, and biosimilars are seen as a potential safety valve that can relieve some of the pressure on a healthcare system that is creaking under the weight of declining resources, increasing demands and expensive new product launches.


Caught in the middle of this are the payers, an important stakeholder group whose voice and insight is critically important in understanding the opportunities, challenges and critical success factors that companies operating in the US biosimilars market need to know and understand.

With the US lagging behind many other developed nations in terms of making biosimilars available to its healthcare system, it’s perhaps ironic that recent events have put opportunities and challenges within the US biosimilars market firmly on the pharma industry’s radar. Five 351(k) submissions have now been made to the FDA, and a biosimilar has been approved – filgrastim-sndz from Sandoz, called Zarxio. Companies are partnering and acquiring assets that will allow them to maximise the opportunities, and investors in biosimilar companies have been cheered by share price surges and forecasts from some leading investment banks claiming that biosimilars in the US are on the cusp of greatness.

Biosimilars: US Payer Perspectives provides a much needed tonic to perhaps the overly optimistic sentiment that has seeped into the discussions about the US biosimilars opportunity. Critically it provides unique payer insights on some of the critical market shaping issues that are dominating discussions, including pricing, substitution, switching, indication extrapolation, naming and originator company defensive tactics.

The US market holds many opportunities for biosimilar developers, but in order to leverage these opportunities and maximise chances of success, biosimilar developers and originator companies must read this report to understand what payers really think, and how they will act in response to cheaper biologics becoming available.







Top Takeaways

Understand what payers are focused on in their efforts to cut the costs of biologic therapies on their plans, and how they would prefer to make savings in order to limit disruption to their members
Identify what payers perceive as the biggest drivers and resistors to biosimilar usage in the US, and how health plan design and payer activities could shape the biosimilars market in the US
Learn what payers believe are the critical success factors in the US biosimilars market, including pricing strategies, educational efforts, physician engagement and provision of clinical data
Benchmark potential pricing, market share and source of business across five key classes of product, including modern insulin, filgrastim, EPO-alfa, oncology mAbs and non-oncology mAbs



Get Answers to Critical Questions

What current strategies for cost-containment in biologic therapy are being used by payers in the US?
How do payers expect to manage inclusion of biosimilars on to their formularies, and what critical pieces of information will they need to see before making any decisions?
From the payers’ perspective, what are the current levels of awareness, familiarity and acceptance of biosimilars at the payer and physician level, both personally and generally across each stakeholder group?
What do payers see as the key drivers and resistors of biosimilar usage in the US?
Do payers agree with the current US Food and Drug Administration (FDA) requirements for biosimilars, and what are their expectations for future regulatory refinements?
What do US payers see as the most important reimbursement challenges for biosimilars, including insights on rebating and payment models?
How do payers expect pricing dynamics within the US biosimilars market to evolve, and what are their expectations in relation to the pricing of originator biologics in response to biosimilar competition?
What are the views of US payers in relation to the key market shaping issues of switching, automatic substitution, extrapolation of indications and biosimilar naming?
What do US payers see as the critical success factors for the US biosimilars market, both from a biosimilar and originator biologic manufacturer perspective?


Experts Interviewed

FirstWord interviewed 12 payers and also sought the opinions of a range of commercial, regulatory, legal and clinical experts to deliver contemporary, actionable and robust insight on the US biosimilars market:

Pharmacy Director, Health Plan Division; Pharmacy Benefit Manager
Chief Medical Officer & Chair of P&T Committee; Regional Health Plan
VP, Pharmacy Services; Managed Care Organisation
Executive VP, Rx Analytics; Pharmacy Benefit Manager
Chief Medical Officer; Integrated Delivery Network
VP, Formulary Management; Medicaid Plan
National Senior Medical Director; Managed Care Organisation
Pharmacy Director; Managed Care Organisation
Medical Director; Managed Care Organisation
Chief Pharmacy Officer; Pharmacy Benefit Manager
Pharmacy Director; Regional Health Plan
Pharmacy Director; Managed Care Organisation

About FirstWord Reports

FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.

FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. FirstWord Reports provide expert views and intelligence on the challenges facing pharma today in these topic areas: Biosimilars, Market Access, Medical Affairs, Sales & Marketing, Technology, Therapy Areas.
FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.

Learn more at www.firstwordgroup.com.


Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
Get This Report
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Biosimilars Market by Product, Manufacturing, Application - Global Forecast to 2021

Biosimilars Market by Product, Manufacturing, Application - Global Forecast to 2021

  • $ 5650
  • Industry report
  • January 2017
  • by MarketsandMarkets

Biosimilars Market by Product (Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon), glycosylated (mAb, EPO), Peptides (Glucagon, Calcitonin)), Manufacturing (In-House, CM0) & Application ...

Biosimilars Market, Europe, Forecast to 2025

Biosimilars Market, Europe, Forecast to 2025

  • $ 4950
  • Industry report
  • March 2017
  • by Frost & Sullivan

A Growing Number of Incentive Policies to Propel Growth in the Next 5–7 Years, with Oncology as the Fastest Adopter Patent expiration and increased use of traditional generic drugs are leading to a ...

Global Biosimilar Drugs Market Analysis 2016 - Forecast to 2022

Global Biosimilar Drugs Market Analysis 2016 - Forecast to 2022

  • $ 4550
  • Industry report
  • January 2017
  • by Hoovers Research

Hoovers Research analysis is one of the most accurate studies performed using the combinational analytical tools. The report contains up to date financial data derived from varied research sources to present ...


Download Unlimited Documents from Trusted Public Sources

Biosimilar Industry

  • April 2017
    26 pages
  • Biosimilar  

    Therapy  

    Monoclonal Anti...  

View report >

Biosimilar Industry in the UK - Forecast

  • April 2017
    12 pages
  • Biosimilar  

    Monoclonal Anti...  

  • United Kingdom  

    Europe  

View report >

Biosimilar Industry in Europe

  • March 2017
    14 pages
  • Biosimilar  

  • Europe  

View report >

Biosimilar Forecast

3 months ago

Related Market Segments :

Biosimilar

ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.